Clinical and Translational Oncology

, Volume 12, Issue 11, pp 753–759 | Cite as

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

  • Cristina Quero Blanco
  • Ramón García Arroyo
  • Mariano Provencio Pulla
  • Antonio Rueda Domínguez
  • Dolores Isla Casado
Clinical Guides in Oncology


Hodgkin’s lymphoma is a malignant disease with an incidence of 2.2 cases/100,000. The main goals of staging are to measure the extent of disease and associated prognostic factors. Distinct recommendations were produced for initial work-up, first-line therapy of early and advanced stage disease and treatment of relapsed or resistant patients.


Hodgkin’s lymphoma Clinical guideline Early-stage Advanced-stage Favourable prognosis Unfavourable prognosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Swerdlow SH, Campo E, Harris NL et al (eds) (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
  2. 2.
    Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636PubMedGoogle Scholar
  3. 3.
    Cosset JM, Henry-Amar M, Meerwaldt JH et al (1992) The EORTC trials for limited stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 28A:1847CrossRefPubMedGoogle Scholar
  4. 4.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514CrossRefPubMedGoogle Scholar
  5. 5.
    Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefPubMedGoogle Scholar
  6. 6.
    Engert A, Franklin J, Eich HT et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25:3495–3502CrossRefPubMedGoogle Scholar
  7. 7.
    Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927CrossRefPubMedGoogle Scholar
  8. 8.
    Engert A, Diehl V, Pluetschow A et al (2009) Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10. Blood (ASH Annual Meeting Abstracts) 114:716Google Scholar
  9. 9.
    Straus DJ, Portlock CS, Qin J et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489CrossRefPubMedGoogle Scholar
  10. 10.
    Pavlovsky S, Maschio M, Santarelli M et al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 80:1466–1473CrossRefPubMedGoogle Scholar
  11. 11.
    Noordijk EM, Thomas J, Foerme MB et al (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (abstract). Proc Am Soc Clin Oncol 16:6505Google Scholar
  12. 12.
    Canellos GP, Anderson JR, Propert K et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478–1484CrossRefPubMedGoogle Scholar
  13. 13.
    Diehl V, Franklin J, Pfistner B et al (2007) 10-year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. 7th International Symposium on Hodgkin Lymphoma, Cologne. Haematologica 92[Suppl 5]:69 [Abstract P114]Google Scholar
  14. 14.
    Loeffler M, Brosteanu O, Hasenclever D et al (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. J Clin Oncol 16:818–829PubMedGoogle Scholar
  15. 15.
    Andrieu JM, Yilma U, Colonna P et al (1999) MOPP versus ABVD and low-dose versus highdose irradiation in Hodgkin’s disease. J Clin Oncol 17:730–732PubMedGoogle Scholar
  16. 16.
    Aleman BMP, Raemaekers JMM, Tirelli U et al (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–2406CrossRefPubMedGoogle Scholar
  17. 17.
    Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BLNI randomized trial. Lancet 341:1051–1054CrossRefPubMedGoogle Scholar
  18. 18.
    Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet 359:2065–2071CrossRefPubMedGoogle Scholar
  19. 19.
    Longo L, Duffey PL, Young RC et al (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218PubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Cristina Quero Blanco
    • 1
  • Ramón García Arroyo
    • 2
  • Mariano Provencio Pulla
    • 3
  • Antonio Rueda Domínguez
    • 4
  • Dolores Isla Casado
    • 5
  1. 1.Servicio de Oncología MédicaHospital Clínico Universitario Virgen de la VictoriaMálagaSpain
  2. 2.Servicio de Oncología MédicaComplejo HospitalarioPontevedraSpain
  3. 3.Servicio de Oncología MédicaHospital Universitario Puerta de HierroMajadahonda, MadridSpain
  4. 4.Servicio de Oncología MédicaHospital Costa del Sol de MarbellaMarbella, MálagaSpain
  5. 5.Servicio de Oncología MédicaHospital Clínico Universitario Lozano BlesaZaragozaSpain

Personalised recommendations